Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Efavirenz

J C Adkins1, S Noble

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|January 8, 1999
PubMed
Summary
This summary is machine-generated.

Efavirenz, a non-nucleoside reverse transcriptase inhibitor, effectively reduces HIV-1 RNA levels. However, drug interactions and resistance mutations necessitate careful patient management and dosage adjustments for optimal treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with demonstrated activity against Human Immunodeficiency Virus type 1 (HIV-1).
  • Emerging HIV-1 variants with mutations in the reverse transcriptase enzyme can exhibit reduced susceptibility to efavirenz.
  • The resistance profile of efavirenz shows cross-resistance with other NNRTIs like nevirapine and delavirdine.

Purpose of the Study:

  • To evaluate the efficacy and safety of efavirenz in HIV-1 infected patients.
  • To assess the impact of efavirenz on viral load and CD4+ cell counts.
  • To identify potential drug interactions and adverse events associated with efavirenz-based regimens.

Main Methods:

  • Clinical trials involving HIV-1 infected patients treated with efavirenz-containing antiretroviral regimens.

Related Experiment Videos

  • Monitoring of HIV RNA plasma levels and CD4+ cell counts.
  • Assessment of drug-drug interactions and adverse event profiles.

    • Main Results:

    • Once-daily efavirenz combined with zidovudine/lamivudine, indinavir, or nelfinavir significantly increased CD4+ cell counts and reduced HIV RNA to below quantifiable levels (< 400 copies/ml).
    • Sustained viral load reduction was observed for at least 72 weeks in one study.
    • Clinically significant drug interactions were noted with indinavir and saquinavir, with dosage adjustments recommended for indinavir.
    • Nervous system symptoms and dermatological effects were the most frequently reported adverse events.

    Conclusions:

    • Efavirenz is an effective component of combination antiretroviral therapy for HIV-1 infection, leading to significant viral suppression and immune reconstitution.
    • Careful consideration of potential drug interactions, particularly with protease inhibitors, and monitoring for adverse events are crucial for efavirenz therapy.
    • The emergence of resistance mutations necessitates ongoing surveillance and strategic treatment planning.